...
search icon
vrca-img

Verrica Pharmaceuticals Inc Share Price

VRCA
NAQ
$6.3
+$0.23
(3.79%)
1D
Industry: Pharmaceuticals Sector: Health Care

Verrica Pharmaceuticals Inc Analyst Forecast

Verrica Pharmaceuticals Inc Share Price Chart

Verrica Pharmaceuticals Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$97.06M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
74.95K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.44
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.28 L
$9.82 H
$6.3

About Verrica Pharmaceuticals Inc, Common Stock

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. more

Industry: PharmaceuticalsSector: Health Care

Verrica Pharmaceuticals Inc Stock Returns

Time FrameVRCASectorS&P500
1-Week Return13.31%1.07%0.74%
1-Month Return-20.65%1.46%1.28%
3-Month Return40.62%3.51%3.6%
6-Month Return4.13%15.29%7.31%
1-Year Return-14.86%7.7%11.97%
3-Year Return-92.46%21.02%72.07%
5-Year Return-95.77%37.81%76.01%
10-Year Return-96.4%139.15%258.47%

Verrica Pharmaceuticals Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue12.00M12.00M9.03M5.12M7.57M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":75.27,"profit":true},{"date":"2023-12-31","value":42.7,"profit":true},{"date":"2024-12-31","value":63.05,"profit":true}]
Cost of Revenue229.00K472.00K725.00K746.00K2.74M[{"date":"2020-12-31","value":8.36,"profit":true},{"date":"2021-12-31","value":17.23,"profit":true},{"date":"2022-12-31","value":26.46,"profit":true},{"date":"2023-12-31","value":27.23,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(229.00K)11.53M8.31M4.38M4.83M[{"date":"2020-12-31","value":-1.99,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.06,"profit":true},{"date":"2023-12-31","value":37.98,"profit":true},{"date":"2024-12-31","value":41.86,"profit":true}]
Gross Margin(1.91%)96.07%91.97%85.44%63.79%[{"date":"2020-12-31","value":-1.99,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.74,"profit":true},{"date":"2023-12-31","value":88.94,"profit":true},{"date":"2024-12-31","value":66.4,"profit":true}]
Operating Expenses39.95M42.44M29.60M70.14M70.75M[{"date":"2020-12-31","value":56.47,"profit":true},{"date":"2021-12-31","value":59.98,"profit":true},{"date":"2022-12-31","value":41.84,"profit":true},{"date":"2023-12-31","value":99.14,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(40.18M)(30.91M)(21.30M)(65.76M)(65.92M)[{"date":"2020-12-31","value":-4018100000,"profit":false},{"date":"2021-12-31","value":-3090800000,"profit":false},{"date":"2022-12-31","value":-2129600000,"profit":false},{"date":"2023-12-31","value":-6575900000,"profit":false},{"date":"2024-12-31","value":-6591900000,"profit":false}]
Total Non-Operating Income/Expense(5.03M)(8.34M)(4.89M)(659.00K)(18.66M)[{"date":"2020-12-31","value":-502500000,"profit":false},{"date":"2021-12-31","value":-834400000,"profit":false},{"date":"2022-12-31","value":-488700000,"profit":false},{"date":"2023-12-31","value":-65900000,"profit":false},{"date":"2024-12-31","value":-1865500000,"profit":false}]
Pre-Tax Income(42.69M)(35.08M)(24.49M)(67.00M)(76.58M)[{"date":"2020-12-31","value":-4269400000,"profit":false},{"date":"2021-12-31","value":-3508000000,"profit":false},{"date":"2022-12-31","value":-2448700000,"profit":false},{"date":"2023-12-31","value":-6699500000,"profit":false},{"date":"2024-12-31","value":-7657900000,"profit":false}]
Income Taxes2.80M3.82M3.19M668.11K-[{"date":"2020-12-31","value":73.32,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":83.47,"profit":true},{"date":"2023-12-31","value":17.48,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(45.50M)(38.90M)(27.68M)(67.66M)-[{"date":"2020-12-31","value":-4549700000,"profit":false},{"date":"2021-12-31","value":-3890300000,"profit":false},{"date":"2022-12-31","value":-2767800000,"profit":false},{"date":"2023-12-31","value":-6766310500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(42.69M)(35.08M)(24.49M)(48.31M)(76.58M)[{"date":"2020-12-31","value":-4269400000,"profit":false},{"date":"2021-12-31","value":-3508000000,"profit":false},{"date":"2022-12-31","value":-2448700000,"profit":false},{"date":"2023-12-31","value":-4831300000,"profit":false},{"date":"2024-12-31","value":-7657900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(45.50M)(35.08M)(24.49M)(67.00M)(76.58M)[{"date":"2020-12-31","value":-4549700000,"profit":false},{"date":"2021-12-31","value":-3508000000,"profit":false},{"date":"2022-12-31","value":-2448700000,"profit":false},{"date":"2023-12-31","value":-6699500000,"profit":false},{"date":"2024-12-31","value":-7657900000,"profit":false}]
EPS (Diluted)(1.71)(1.29)(0.79)(1.46)(1.50)[{"date":"2020-12-31","value":-171,"profit":false},{"date":"2021-12-31","value":-129,"profit":false},{"date":"2022-12-31","value":-79,"profit":false},{"date":"2023-12-31","value":-146,"profit":false},{"date":"2024-12-31","value":-150.13,"profit":false}]

Verrica Pharmaceuticals Inc Ratios

Verrica Pharmaceuticals Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

VRCA
Cash Ratio 0.73
Current Ratio 1.25
Quick Ratio 1.18

Verrica Pharmaceuticals Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VRCA
ROA (LTM) -26.28%
ROE (LTM) -1546.58%

Verrica Pharmaceuticals Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VRCA
Debt Ratio Lower is generally better. Negative is bad. 1.42
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.42

Verrica Pharmaceuticals Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VRCA
Trailing PE NM
Forward PE NM
P/S (TTM) 3.15
P/B 238.54
Price/FCF 10
EV/R 3.43
EV/Ebitda NM

FAQs

What is Verrica Pharmaceuticals Inc share price today?

Verrica Pharmaceuticals Inc (VRCA) share price today is $6.3

Can Indians buy Verrica Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Verrica Pharmaceuticals Inc (VRCA) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VRCA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Verrica Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Verrica Pharmaceuticals Inc (VRCA) via the Vested app. You can start investing in Verrica Pharmaceuticals Inc (VRCA) with a minimum investment of $1.

How to invest in Verrica Pharmaceuticals Inc shares from India?

You can invest in shares of Verrica Pharmaceuticals Inc (VRCA) via Vested in three simple steps:

  • Click on Sign Up or Invest in VRCA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Verrica Pharmaceuticals Inc shares
What is Verrica Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Verrica Pharmaceuticals Inc (VRCA) is $9.82. The 52-week low price of Verrica Pharmaceuticals Inc (VRCA) is $3.28.

What is Verrica Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Verrica Pharmaceuticals Inc (VRCA) is

What is Verrica Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Verrica Pharmaceuticals Inc (VRCA) is 238.54

What is Verrica Pharmaceuticals Inc dividend yield?

The dividend yield of Verrica Pharmaceuticals Inc (VRCA) is 0.00%

What is the Market Cap of Verrica Pharmaceuticals Inc?

The market capitalization of Verrica Pharmaceuticals Inc (VRCA) is $97.06M

What is Verrica Pharmaceuticals Inc's stock symbol?

The stock symbol (or ticker) of Verrica Pharmaceuticals Inc is VRCA

How Can Investors Use Verrica Pharmaceuticals Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Verrica Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Verrica Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Verrica Pharmaceuticals Inc shares for Indian investors?

When investing in Verrica Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Verrica Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Verrica Pharmaceuticals Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Verrica Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Verrica Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top